European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...
News Medical on MSN
Boosting First Responder Cells May Aid Cancer Therapy
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
OncoHost, a global leader in precision oncology and proteomics-based biomarker development, today announced the presentation of two new research posters at the 2025 International Society for Liquid ...
4d
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...
Farber-co-led phase 3 trial shows that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant ...
Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
News-Medical.Net on MSN
Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy
Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...
Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback